Search for: "In Re: Humira (Adalimumab) Antitrust Litigation" Results 1 - 2 of 2
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
Seventh Circuit to Determine Whether the Sherman Act Can Mow Down Drug “Patent Thickets”
9 Aug 2021, 2:02 am by Deb Givens
  In Re: Humira (Adalimumab) Antitrust Litigation, concerns Humira, a biologic therapy developed and marketed by AbbVie to treat rheumatoid arthritis. [read post]
Antitrust Today - https://constantinecannon.com/practice/antitrust-litigation-counseling/antitrust-today/
Pharma & Biotech GWiR 9 January 2009 from IP Think Tank
9 Jan 2009, 3:00 am
You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: [duncanbucknell.com]   Highlights this week included: Humira (Adalimumab) – US: Bayer HealthCare files patent infringement suit against Abbott Laboratories over Humira; Abbott fires back with lawsuit claiming Bayer’s patent invalid, not infringed or unenforceable (Law360) (Law360) (Philip Brooks' Patent Infringement Updates) (Patent Baristas)… [read post]
IP Thinktank - http://duncanbucknell.com/ipthinktank.blog